Melior Discovery, Inc. announced today the United States Patent and Trademark Office (USTPO) has awarded a Notice of Allowance for a broad patent application covering the Company's use of MLR-1023 for, among other things, the treatment of type II diabetes and obesity. The patent will cover use of MLR-1023 for the treatment of type II diabetes, obesity and metabolic syndrome, including its use in combination with other compounds and as a component in other drugs.
"This recent patent notification offers the potential for robust patent protection for MLR-1023, Melior's lead drug candidate for diabetes, and represents a significant milestone for the Company," said Andrew Reaume PhD, President and CEO of Melior Discovery.
Diabetes medication shows promise in reducing alcohol use